

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/262186 A1

(43) International Publication Date
30 December 2021 (30.12.2021)

(51) International Patent Classification:

A61K 38/24 (2006.01) *A61P 5/06* (2006.01)

(21) International Application Number:

PCT/US2020/039745

(22) International Filing Date:

26 June 2020 (26.06.2020)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **FERRING B.V.** [NL/NL]; Polaris Avenue 144,
2132 JX Hoofddorp (NL).

(72) Inventor: **HEISER, Patrick**; Ferring International Phar-
mascience Center, 100 Interpace Parkway, Parsippany, New
York 07054 (US).

(74) Agent: **HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB** et al.; Arabellastr. 30,
81925 München (DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to non-prejudicial disclosures or exceptions to lack of
novelty (Rule 4.17(v))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: HP-HMG FOR USE IN THE TREATMENT OF INFERTILITY IN A PATIENT WITH POLYCYSTIC OVARY SYNDROME

(57) Abstract: Described are assisted reproductive technology compositions and methods using highly purified menotropin (HP-hMG) to stimulate follicle development, particularly in women who have been diagnosed with oligoovulation and/or PCOS and who are predicted to have a high ovarian response to controlled ovarian stimulation.



WO 2021/262186 A1